82 related articles for article (PubMed ID: 20622483)
1. [FLT3 kinase inhibitors for the treatment of acute leukemia].
Kiyoi H
Rinsho Ketsueki; 2010 Jun; 51(6):384-9. PubMed ID: 20622483
[No Abstract] [Full Text] [Related]
2. [Possibility of targeting FLT3 kinase for the treatment of leukemia].
Kiyoi H
Rinsho Ketsueki; 2005 Mar; 46(3):187-97. PubMed ID: 16447713
[No Abstract] [Full Text] [Related]
3. [The present status of, and problems with the development of FLT3 kinase inhibitors].
Kiyoi H
Rinsho Ketsueki; 2006 Apr; 47(4):270-7. PubMed ID: 16715961
[No Abstract] [Full Text] [Related]
4. [New therapeutic option for leukemia patients, with FLT3/Aurora kinase inhibitor, KW-2449: strategy and comparison with other kinase inhibitors].
Shiotsu Y
Rinsho Ketsueki; 2008 Aug; 49(8):641-9. PubMed ID: 18800614
[No Abstract] [Full Text] [Related]
5. Can FLT3 inhibitors overcome resistance in AML?
Tam WF; Gary Gilliland D
Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
[TBL] [Abstract][Full Text] [Related]
6. [Novel molecularly target therapies for leukemia].
Kiyoi H
Nihon Rinsho; 2007 Jan; 65 Suppl 1():611-6. PubMed ID: 17474469
[No Abstract] [Full Text] [Related]
7. Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.
de Vries AC; Stam RW; Schneider P; Niemeyer CM; van Wering ER; Haas OA; Kratz CP; den Boer ML; Pieters R; van den Heuvel-Eibrink MM
Haematologica; 2007 Nov; 92(11):1557-60. PubMed ID: 18024405
[TBL] [Abstract][Full Text] [Related]
8. Midostaurin for patients with acute myeloid leukemia and FLT3 mutations.
Levis MJ
Clin Adv Hematol Oncol; 2019 Jun; 17(6):323-325. PubMed ID: 31437132
[No Abstract] [Full Text] [Related]
9. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
10. FLT3 inhibition as a targeted therapy for acute myeloid leukemia.
Sanz M; Burnett A; Lo-Coco F; Löwenberg B
Curr Opin Oncol; 2009 Nov; 21(6):594-600. PubMed ID: 19684517
[TBL] [Abstract][Full Text] [Related]
11. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
Kajiguchi T; Chung EJ; Lee S; Stine A; Kiyoi H; Naoe T; Levis MJ; Neckers L; Trepel JB
Leukemia; 2007 Dec; 21(12):2476-84. PubMed ID: 17851558
[TBL] [Abstract][Full Text] [Related]
12. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
14. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
15. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
16. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
17. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.
Cheng Y; Paz K
IDrugs; 2008 Jan; 11(1):46-56. PubMed ID: 18175263
[TBL] [Abstract][Full Text] [Related]
18. Small molecule FLT3 tyrosine kinase inhibitors.
Levis M; Small D
Curr Pharm Des; 2004; 10(11):1183-93. PubMed ID: 15078134
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
20. FLT3 inhibitors for acute myeloid leukemia.
Lancet JE
Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
[No Abstract] [Full Text] [Related]
[Next] [New Search]
